Treatment of Perirenal Adenopathy Associated with Schistosoma Hematobium

Diagnostic Considerations

The American Journal of Kidney Diseases recommends testing for appropriate endemic coinfections, such as Salmonella, HBV, HCV, and HIV, as targeted treatment of these may alter the aggressiveness of glomerulonephritis or other sequelae of schistosomiasis 1, 4
Consider kidney biopsy in patients with overt or progressive kidney disease, but biopsy can be deferred in mild disease with empirical antiparasitic treatment, as suggested by the American Journal of Kidney Diseases 4
Detection of parasitic antigens in glomeruli requires specialized laboratories, which should be considered when evaluating the utility of kidney biopsy, according to the American Journal of Kidney Diseases 4

The American Journal of Kidney Diseases recommends administering praziquantel 40 mg/kg orally as a single dose for Schistosoma hematobium infection, although the exact dosage and duration may vary 1, 2
Ensure sufficient dosage and duration to completely eradicate the organism from the body, as recommended by the American Journal of Kidney Diseases 1, 2
No immunosuppressive agents are indicated in schistosomal nephropathy, according to the American Journal of Kidney Diseases 1, 2

Evaluate patients with elevated serum creatinine and/or hematuria for bladder cancer and/or urinary obstruction, which are common complications of S. hematobium infection, as suggested by the American Journal of Kidney Diseases 2

Monitor patients with hepatic fibrosis from schistosomiasis for the development of kidney disease, as recommended by the American Journal of Kidney Diseases 2
Be aware that serology may remain positive for years after successful treatment and cannot be used to assess treatment success, according to Praxis Medical Insights 3